Get the Stockscreener App
2.18
2.35%
0.05
After Hours:
2.09
-0.09
-4.13%
Proqr Therapeutics N V stock is traded at $2.18, with a volume of 175.65K.
It is up +2.35% in the last 24 hours and up +22.47% over the past month.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
See More
Previous Close:
$2.13
Open:
$2.13
24h Volume:
175.65K
Relative Volume:
0.33
Market Cap:
$191.72M
Revenue:
$7.05M
Net Income/Loss:
$-30.43M
P/E Ratio:
-5.755
EPS:
-0.3788
Net Cash Flow:
$21.84M
1W Performance:
+0.93%
1M Performance:
+22.47%
6M Performance:
-21.01%
1Y Performance:
+32.93%
1-Day Range:
$2.1067
$2.18
1-Week Range:
$2.00
$2.5398
52-Week Range:
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.18 | 191.72M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-10-25 | Upgrade | Citigroup | Neutral → Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
Bank of America Corp DE Boosts Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected - simplywall.st
Equities Analysts Offer Predictions for PRQR FY2026 Earnings - MarketBeat
Research Analysts Set Expectations for PRQR FY2026 Earnings - Defense World
Jane Street Group LLC Buys Shares of 11,400 ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Analysts Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $8.00 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Shares Sold by Two Sigma Advisers LP - Defense World
Two Sigma Investments LP Has $1.02 Million Stake in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
Squarepoint Ops LLC Grows Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Two Sigma Investments LP Buys 320,614 Shares of ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of “Buy” by Analysts - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Sees Significant Increase in Short Interest - MarketBeat
ProQR Shareholders Approve Key Resolutions at Annual Meeting - TipRanks
ProQR Therapeutics (NASDAQ:PRQR) Shares Purchased by Northern Trust Corp - MarketBeat
Millennium Management LLC Grows Stock Position in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
BNP Paribas Financial Markets Buys 15,900 Shares of ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Northern Trust Corp Has $1.11 Million Stock Holdings in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Woodline Partners LP Invests $9.43 Million in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
Here's Why ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO May Deserve A Raise - simplywall.st
Millennium Management LLC Buys 2,683,351 Shares of ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Point72 Asset Management L.P. Buys New Position in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year - Investing.com Canada
Cantor Fitzgerald Issues Negative Forecast for PRQR Earnings - MarketBeat
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes Position in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Oppenheimer Has Lowered Expectations for ProQR Therapeutics (NASDAQ:PRQR) Stock Price - Defense World
Research Analysts Issue Forecasts for PRQR FY2025 Earnings - Defense World
ProQR (PRQR) Price Target Cut by Oppenheimer Amid Clinical Updates | PRQR Stock News - GuruFocus
DAFNA Capital Management LLC Buys 661,979 Shares of ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | - GuruFocus
Oppenheimer Adjusts ProQR Therapeutics N.V Price Target to $9 From $15, Maintains Outperform Rating - marketscreener.com
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences - GlobeNewswire
Raymond James Financial Inc. Invests $260,000 in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of “Buy” from Analysts - Defense World
ProQR: Q1 Earnings Snapshot - News-Times
1,181,413 Shares in ProQR Therapeutics (NASDAQ:PRQR) Acquired by ArrowMark Colorado Holdings LLC - MarketBeat
New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR) - simplywall.st
ProQR Therapeutics NV earnings missed, revenue topped estimates - Investing.com Australia
ProQR Therapeutics NV earnings missed, revenue topped estimates By Investing.com - Investing.com Nigeria
ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):